Results 61 to 70 of about 28,367 (198)

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis

Genome Medicine
Background Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of ...
Camus Nimmo, Arturo Torres Ortiz, Cedric C. S. Tan, Juanita Pang, Mislav Acman, James Millard, Nesri Padayatchi, Alison D. Grant, Max O’Donnell, Alex Pym, Ola B. Brynildsrud, Vegard Eldholm, Louis Grandjean, Xavier Didelot, François Balloux, Lucy van Dorp   +15 more
doaj   +1 more source

Bedaquiline Effect Towards QT Interval in Drug Resistant Tuberculosis (DR-TB): A Systematic Review

Siriraj Medical Journal, 2023
Objective: Bedaquiline is recommended by World Health Organization (WHO) to treat Drug-Resistant Tuberculosis (DR-TB). Bedaquiline is chosen due to its efficacy and safety in numerous studies.
Arya Marganda Simanjuntak, Rahmadini Aulia, Dhewa Triguna Banjarnahor, Riski Dimas Harianja, Indra Yovi   +4 more
doaj  

Recurrent Pneumothorax With Bronchopleural Fistula in Primary Multidrug‐Resistant Pulmonary Tuberculosis: A Challenging Case

Respirology Case Reports, Volume 14, Issue 5, May 2026.
A 41‐year‐old man with primary multidrug‐resistant pulmonary tuberculosis (MDR‐TB) developed recurrent pneumothorax and a bronchopleural fistula (BPF). Despite persistent air leak (PAL) after initial video‐assisted thoracoscopic surgery (VATS), definitive open thoracotomy with decortication and fistula repair led to sustained lung re‐expansion.
Primawati, Winariani Koesoemoprodjo, Mohamad Rizki   +2 more
wiley   +1 more source

Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).

, 2019
Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).
Leonie Van Zyl (7512503), Elizabeth J. Ragan (5662181), Karen R. Jacobson (7512512), Tara C. Bouton (7512494), Laura F. White (7512500), Margaretha de Vos (7512497), C. Robert Horsburgh (7512506), Robin M. Warren (7512509), Danie Theron (497398)   +8 more
core   +1 more source

Bedaquiline: what might the future hold? [PDF]

Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis ...
Shaw, Emily S, Conradie, Francesca, Pinto, Lancelot, Sloan, Derek J, Leslie, Alasdair, Chiang, Chen-Yuan, Lipman, Marc, Esmail, Hanif, Potter, Jessica L, Warren, Robin M, Tweed, Conor D, Stoker, Neil G, Voo, Teck Chuan, Lange, Christoph, Claassen, Helgard, Lebina, Limakatso, Theron, Grant, Rucsineanu, Oxana, Tisile, Phumeza   +18 more
core   +3 more sources

Growth Differentiation Factor‐15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid‐Containing Regimen

The Clinical Respiratory Journal, Volume 20, Issue 5, May 2026.
Baseline GDF‐15 predicts linezolid‐induced myelosuppression in rifampicin‐resistant tuberculosis. Patients with higher pretreatment GDF‐15 (> 950 pg/mL) were more likely to develop significant hemoglobin decline during therapy. Measuring GDF‐15 before treatment may help identify high‐risk patients and guide safer, personalized linezolid use.
Amaylia Oehadian, Prayudi Santoso, Delita Prihatni, Andini Kartikasari, Ida Parwati, Diah Handayani, Thomas Handoyo, Noorwati Sutandiyo, Bachti Alisjahbana, Dick Menzies, Rovina Ruslami   +10 more
wiley   +1 more source

Bedaquiline, linezolid, pretomanid: their adverse events [PDF]

, 2020
The article discusses the clinical cases and tactics of treatment with bedaquiline, linezolid, and pretomanid in patients with multiple and extensive drug resistance.
Саргсян, В. С., Ponomarenko, A. D., Блохина, А. А., Пономаренко, А. Д., Sargsyan, V. S., Blokhina, A. A., Сабадаш, Е. В., Sabadash, E. V   +7 more
core  

QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions

Pharmacology and Clinical Pharmacy Research
Background: The cardiac safety of regimens containing bedaquiline and delamanid is not well-established, especially in Indonesia.  This study aimed to analyze QTc interval during six months of treatment and factors associated with QTc interval ...
Oki Nugraha Putra
doaj   +1 more source

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

EClinicalMedicine, 2020
Background: Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in ...
Erika Mohr-Holland, Anja Reuter, Jennifer Furin, Anthony Garcia-Prats, Virginia De Azevedo, Vanessa Mudaly, Yulene Kock, Laura Trivino-Duran, Petros Isaakidis, Jennifer Hughes   +9 more
doaj   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, Volume 15, Issue 14, 10 April 2026.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source